Search Results

First-in-Human REVELUTION Data Presented for Medtronic's Drug-Filled Stent

October 31, 2016—The first-in-human REVELUTION study of Medtronic plc’s new polymer-free, drug-filled stent (DFS) indicated noninferior in-stent late lumen loss at 9-months compared with historical data of Medtronic’s Resolute zotarolimus-eluting stent (ZES).

Abbott’s Navitor TAVR System Approved in Europe for Low- and Intermediate-Risk Patients

August 29, 2025—Abbott announced it has received European CE Mark approval for an expanded indication for the company’s Navitor transcatheter aortic valve replacement (TAVR) system to treat patients with symptomatic, severe aortic stenosis who are at low or intermediate risk for open heart surgery.